Online inquiry

IVTScrip™ mRNA-Anti-TNFSF4, R4930(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13637MR)

This product GTTS-WQ13637MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets TNFSF4 gene. The antibody can be applied in Allergic asthma, Allergic rhinitis research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001297562.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7292
UniProt ID P23510
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFSF4, R4930(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ13637MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14289MR IVTScrip™ mRNA-Anti-CSF1R, RG7155(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA RG7155
GTTS-WQ8329MR IVTScrip™ mRNA-Anti-TFRC, HN-66000(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA HN-66000
GTTS-WQ6272MR IVTScrip™ mRNA-Anti-HA, CR-6261(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CR-6261
GTTS-WQ8330MR IVTScrip™ mRNA-Anti-TFRC, HN-66000(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA HN-66000
GTTS-WQ14873MR IVTScrip™ mRNA-Anti-SLC39A6, SGN-LIV1A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SGN-LIV1A
GTTS-WQ10524MR IVTScrip™ mRNA-Anti-PCSK9, LY-3015014(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LY-3015014
GTTS-WQ1719MR IVTScrip™ mRNA-Anti-CD40, ADC-1013(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ADC-1013
GTTS-WQ5110MR IVTScrip™ mRNA-Anti-CD52, Campath-1H(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA Campath-1H
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW